Emerging treatments for age-related macular degeneration

20 September 2017
Volume 18, Issue 3

This narrative review summarises emerging interventions that may be mentioned in the popular and professional press, and may be on our menu of treatment options to discuss with patients in the near future.


When optometry and medical students are taught at university, a dramatic caveat should be added to much of what they learn: that it will be of no use in their careers to come. Knowledge is constantly replaced or updated, and clinical skills are at risk of being superseded by technology: for example, the time-honoured art of direct ophthalmoscopy may be on the verge of redundancy (Purbrick and Chong 2015). Age-related macular degeneration (AMD) is the commonest cause of visual impairment in the western world, and is becoming an increasing public health challenge in Asia (Velez-Montoya et al. 2014). The management of AMD underwent a paradigm shift in 2006 with the advent of antivascular endothelial growth factor treatments (anti-VEGFs) and optical coherence tomography (OCT).

Sign in to continue

Forgotten password?

Sign in to view the article

Not a member? Start enjoying the benefits of College membership today. Take a look at what the College can offer you and view our membership categories and rates.

Related further reading

Jane Veys MCOptom on reducing the tears and fears of our patients

Adrian O’Dowd explores a new treatment for late-stage dry AMD being considered for approved use in the UK that could raise hopes of delaying the irreversible sight loss caused by the disease.


In each issue, Acuity poses a topical question on a tricky scenario to a panel of members.